Get started
Author

P.M. Forde

OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
2022 · B. Besse, M.M. Awad, et al. · Journal of Thoracic Oncology · 11
929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
2022 · J. Spicer, T. Cascone, et al. · Annals of Oncology · 9
1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
2024 · J. Reuss, C.H. Leung, et al. · Annals of Oncology · 3
LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY
2026 · B. Besse, E. Felip, et al. · ESMO Open · 2
PDF
P1.11.72 Phase II Study of Combination Azacitidine and Entinostat and Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
2025 · K.A. Marrone, B. Landon, et al. · Journal of Thoracic Oncology · 2
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC
2022 · P. Huang, P.B. Illei, et al. · Journal of Thoracic Oncology · 2
1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
2022 · P.M. Forde, A. Atmaca, et al. · Annals of Oncology · 1
P1.139: Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy by Metabolic Response Status in Checkmate 816
2026 · J.D. Spicer, P.M. Forde, et al. · Journal of Thoracic Oncology
OA12.03 Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Resectable Diffuse Pleural Mesothelioma
2025 · J. Reuss, R.J. Mehran, et al. · Journal of Thoracic Oncology
MA09.04 Differential CD8+FoxP3+ T Cell Infiltration Patterns Associate with Pathologic Response after Neoadjuvant Anti-PD-1 in NSCLC
2024 · M. Fotheringham, B. Green, et al. · Journal of Thoracic Oncology
PDF
Patterns of Failure in Resectable Stage I-IIIA NSCLC Treated with Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial
2022 · S. Mao, S. Rosner, et al. · International Journal of Radiation Oncology*Biology*Physics
Works count: 12
Citation count: 30
H-index: 3
I10-index: 1
Year
Topic
Type